RecruitingNot ApplicableNCT07522736

Intrathecal Dexmedetomidine With Bupivacaine, in Patients Undergoing Knee Orthopedic Surgery

The Analgesic Effect of Intrathecal Dexmedetomidine With Bupivacaine, in Patients Undergoing Knee Orthopedic Surgery: A Randomized Double-Blinded Dose-Finding Trial


Sponsor

Cairo University

Enrollment

120 participants

Start Date

Mar 1, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

This study aims to compare the duration of analgesia (as the primary outcome) and adverse effects (as the secondary outcome) after intrathecal administration of dexmedetomidine with hyperbaric bupivacaine to patients undergoing knee orthopedic surgery.


Eligibility

Min Age: 18 YearsMax Age: 65 Years

Inclusion Criteria3

  • Age from 18 to 65 years.
  • American Society of Anesthesiologists (ASA) physical status I-II.
  • Male patients scheduled for knee orthopedic surgery.

Exclusion Criteria5

  • Patients with psychiatric disorders.
  • History of drug addiction.
  • Contraindication for regional anesthesia.
  • History of hypersensitivity to the study drugs.
  • Previous administration of opioids and/or other central nervous system depressants during current hospital admission.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDexmedetomidine 4 μg

Patients will receive intrathecal hyperbaric bupivacaine 15 mg, supplemented with dexmedetomidine 4 μg.

DRUGDexmedetomidine 8 μg

Patients will receive intrathecal hyperbaric bupivacaine 15 mg, supplemented with dexmedetomidine 8 μg.

DRUGDexmedetomidine 12 μg

Patients will receive intrathecal hyperbaric bupivacaine 15 mg, supplemented with dexmedetomidine 12 μg.


Locations(1)

Cairo University

Cairo, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07522736


Related Trials